NCT02059057终止不适用
Crossover From IDE Trial CLN0009, Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study, IDE G110066
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 102
- 试验地点
- 48
- 主要终点
- Mean Change in Six Minute Walk Test (6MWT)
研究概览
简要总结
Crossover study for patients who were randomized to the Control Group in CLN0009 (NCT01608490).
详细描述
Provide LVRC procedure to qualifying subjects who were enrolled as Control Subjects in and completed the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009, and obtain safety and effectiveness data on these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 36 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject was enrolled as a Control Subject in and completed all required study assessments through the 12 month visit for the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN
- •Subject has post-bronchodilator FEV1 ≤45% predicted.
- •Subject has residual volume (RV) ≥175% predicted.
- •Subject has stopped smoking for at least 8 weeks prior to entering the study, as confirmed by a Cotinine test or other appropriate diagnostic test.
- •Subject has read, understood and signed the Informed Consent form.
- •Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.
排除标准
- •Subject has severe homogeneous emphysema as determined by the Core Radiology Lab
- •Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g. severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.
- •Subject has a change in FEV1 >20% (or, for subjects with pre-bronchodilator FEV1 below 1 L, a change of > 200 mL) post-bronchodilator, unless investigator can confirm by other means that subject does not have asthma.
- •Subject has DLCO <20% of predicted.
- •Subject has severe gas exchange abnormalities as defined by:
- •PaCO2 >55 mm Hg PaO2 <45 mm Hg on room air (High altitude criterion: PaO2 <30 mm Hg)
- •Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment.
- •Subject has severe pulmonary hypertension. If pulmonary hypertension is present, "severe" is defined by right ventricular systolic pressure >50 mm Hg via right heart catheterization and/or echocardiogram.
- •Subject has an inability to walk >140 meters (150 yards) in 6 minutes.
- •Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
- •Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
- •Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
- •Subject has clinically significant bronchiectasis.
- •Subject has giant bullae >1/3 lung volume.
- •Subject has had previous LVR surgery, lung transplantation, lobectomy, LVR devices or other devices to treat COPD in either lung.
- •Subject has been involved in pulmonary drug or device studies within 30 days prior to this study, with the exception of the RENEW Study.
- •Subject is taking >20 mg prednisone (or equivalent dose of a similar steroid) daily.
- •Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.
- •Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as heparin or Coumadin) which cannot be stopped for seven (7) days prior to procedure.
- •Subject has a sensitivity or allergy to nitinol (nickel-titanium) or its constituent metals.
- •Subject has a known sensitivity to drugs required to perform bronchoscopy.
- •Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).
- •Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.
结局指标
主要结局
Mean Change in Six Minute Walk Test (6MWT)
时间窗: Change in Baseline to 12 months
Mean absolute change from baseline to12 months. The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.
次要结局
- Mean Percent Change in Forced Expiratory Volume in One Second (FEV1)(Change in Baseline to 12 months)
- Mean Change in Residual Volume (RV)(Change in Baseline to 12 months)
- Mean Change in St. Georges Respiratory Questionnaire (SGRQ)(Change in Baseline to 12 months)
研究者
研究点 (48)
Loading locations...
相似试验
已完成
2 期
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological CancersAdvanced Gynecological CancersUterine CancerOvarian CancerCervical CancerNCT03073525Gradalis, Inc.25
已完成
不适用
Lung Ultrasonography vs Fiberoptic Bronchoscopy for Aiding Lung Collapse in Patient Using Double Lumen TubeLung DiseasesUltrasonographyFiberoptic BronchoscopyOne Lung VentilationThoracic SurgeryLung CollapseNCT03314519Mahidol University200
终止
不适用
Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure PatientsHeart FailureNCT02448342Sensible Medical Innovations Ltd.380
已完成
不适用
Mechanisms of Vascular Damage in Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT01020344University of Zurich30
已完成
2 期
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILDSclerodermaIdiopathic Inflammatory MyositisMixed Connective Tissue DiseaseInterstitial Lung DiseaseNCT01862926Royal Brompton & Harefield NHS Foundation Trust104